2022 Drug Trend Report

Our Business

Is Personal

we exist to make medications more affordable for the people who need them

Medications play a vital role in people's lives. They can be lifesaving and life changing. Many Americans struggle with the cost of prescription drugs. At Navitus, this is personal to us. 

As a result, we:

  • Do not mark up drug prices

  • Do not keep any portion of manufacturer rebates

  • Believe customers own their data

Frame 14

 

At Navitus, we approach pharmacy benefits differently. In our experience, when you provide employer plan sponsors and health plans full visibility, they can make better decisions. This helps members afford the medications they need to live their lives more fully.

This year’s report highlights our ability to keep costs well-managed and ensure that people get the care they need.

I invite you to explore the results that Navitus delivered with our client partners.

Brent Eberle
Chief Pharmacy Officer, Navitus Health Solutions

2.6%

Average Net Total Cost¹ Trend for Commercial Clients

$89.73

Net Total Cost Per Member Per Month (PMPM) for Commercial Clients

How We Do It

  • No spread: we only bill clients what we pay pharmacies

  • We pass through 100% of discounts and rebates received

  • We prioritize proven, low cost, clinically appropriate therapies 

  • We innovate new ways to deliver even more savings

Additionally, plans that implemented a limited pharmacy network that included Costco’s 90-day option saved an additional 3-5% on prescription filled at local pharmacies.

 

2023-06-08 14_29_09-Navitus – Figma

 

download the 2022 DRUG TREND EXECUTIVE SUMMARY

METHODOLOGY

The Navitus drug trend is calculated by comparing the net total cost PMPM for 2022 to that for 2021. Net cost PMPM represents full-year (Q1-Q4) data for total member copays and plan paid amounts minus manufacturer rebates and fees. This value is divided by the total number of members and by 12 months of the year.

Net total cost PMPM trend consists of two components: utilization and cost and includes both specialty and non-specialty drugs. Utilization trend measures the change in total days of therapy. Cost trend measures the change in net total drug cost per the above. This analysis included data for more than 500 clients, representing 2.2M members within Navitus’ commercial book of business, including plan sponsors and health plans. To be included, these organizations must have been clients of Navitus in both 2021 and 2022. Exclusions from this analysis include products administered at physicians’ offices, clinics and hospitals, COVID-19 vaccines and supplies and any additional savings from copay assistance programs.